What is Surface Oncology Financial Strength?
Surface Oncology has the Financial Strength Rank of 6.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Surface Oncology did not have earnings to cover the interest expense.
As of today, Surface Oncology's Altman Z-Score is 0.00.
Competitive Comparison of Surface Oncology's Financial Strength
For the Biotechnology subindustry, Surface Oncology's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surface Oncology's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Surface Oncology's Financial Strength distribution charts can be found below:
* The bar in red indicates where Surface Oncology's Financial Strength falls into.
Surface Oncology Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Surface Oncology's Interest Expense for the
months ended in Jun. 2023 was $-3.11 Mil. Its Operating Income for the
months ended in Jun. 2023 was $-22.41 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.00 Mil.
Surface Oncology's Interest Coverage for the quarter that ended in Jun. 2023 is
| Surface Oncology did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Surface Oncology's Debt to Revenue Ratio for the quarter that ended in Jun. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Surface Oncology has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surface Oncology (Surface Oncology) Business Description
Traded in Other Exchanges
N/A
Address
50 Hampshire Street, 8th Floor, Cambridge, MA, USA, 02139
Surface Oncology Inc is a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces in and around tumors in the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Geographically, the activities are carried out throughout the region of the United States.
Executives
| Chandra Adams |
officer: Deputy GC |
SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139 |
| Alison Oneill |
officer: Chief Medical Officer |
|
| Jessica Fees |
officer: See Remarks |
C/O SURFACE ONCOLOGY, ICN., 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA 02139 |
| Robert W. Ross |
officer: Chief Medical Officer |
C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139 |
| Henry C. Rath |
officer: Chief Business Officer |
C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET 8TH FL, CAMBRIDGE MA 02139 |
| Vito J. Palombella |
officer: Chief Scientific Officer |
780 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
| Carsten Brunn |
director |
C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472 |
| Theresa Boni |
officer: General Counsel |
C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139 |
| Benjamin Hickey |
director |
C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121 |
| Liisa I Nogelo |
officer: General Counsel |
C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA 02139 |
| Jeff Goater |
director, officer: Chief Executive Officer |
C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139 |
| Denice Torres |
director |
3 RABBIT RUN DRIVE, NEW HOPE PA 18938 |
| David S. Grayzel |
director |
C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139 |
| Atlas Venture Associates Ix, L.p. |
10 percent owner |
46 WAREHAM STREET, FLOOR 3, BOSTON MA 02118 |
| Atlas Venture Associates Ix, Llc |
10 percent owner |
56 WAREHAM STREET, FLOOR 3, BOSTON MA 02118 |
Surface Oncology (Surface Oncology) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SURF has been successfully added to your